DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 10,031,141
|Title:||VEGF polymorphisms and anti-angiogenesis therapy|
|Abstract:||Methods for determining whether a patient in at particular risk of hypertension associated with anti-VEGF treatment or has a greater likelihood of benefiting from anti-VEGF therapy by screening a sample isolated from the patient for specific genomic polymorphisms.|
|Inventor(s):||Schneider; Bryan P. (Avon, IN), Radovich; Milan (Indianapolis, IN), Sledge; George W. (Indianapolis, IN)|
|Assignee:||Genentech, Inc. (South San Francisco, CA)|
|Patent Claims:||1. A method of treating a human patient suffering from breast cancer, the method comprising: (a) obtaining a sample containing nucleic acid isolated from the patient; (b)
performing a genotyping assay on the sample and detecting the AA genotype at VEGF (-1154G/A) in said patient; (c) identifying said patient having the AA genotype at VEGF (-1154G/A) as having an increased likelihood of benefiting from treatment with
bevacizumab; and (d) administering bevacizumab to the patient.
2. The method of claim 1, further comprising administering an anti-neoplastic composition.
3. The method of claim 1, wherein said breast cancer is metastatic breast cancer.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||Start Trial||Genentech, Inc. (South San Francisco, CA)||2039-02-26||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||Start Trial||Genentech, Inc. (South San Francisco, CA)||2039-02-26||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|South Africa||201003419||Start Trial|
|World Intellectual Property Organization (WIPO)||2009073540||Start Trial|
|World Intellectual Property Organization (WIPO)||2011060998||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.